ADC Therapeutics SA — Form 6-K Summary
Reporting period: Form 6-K furnished February 2, 2023, for February 2023. The filing provides corporate and financing updates and preliminary unaudited results for the three months ended December 31, 2022.
Business Context
ADC Therapeutics is a commercial-stage biotechnology company developing targeted antibody drug conjugates. Its commercial franchise consists of ZYNLONTA (loncastuximab tesirine), approved for certain relapsed or refractory diffuse large B-cell lymphoma indications. Its pipeline includes ADCT-901, ADCT-601, ADCT-212, ADCT-602 and ADCT-701, along with additional preclinical assets and partnered programs.
Financial Metrics
| Metric | Three months ended December 31, 2022 | Comparable period |
|---|---|---|
| Product revenue, net | Approximately $19.8 million | $17.0 million in Q4 2021 |
| Period-over-period revenue change | 16.5% increase | — |
| Cash and cash equivalents | Approximately $326.4 million at December 31, 2022 | Not provided |
The results and cash balance were preliminary, unaudited estimates subject to quarter-end closing adjustments. The filing does not provide clear preliminary values for net income or loss, operating cash flow, margins, total debt, or liquidity runway.
Revenue growth was primarily attributed to higher vial volumes, partially offset by higher gross-to-net sales deductions.
Material Changes and Financing Transactions
- ADC Therapeutics agreed to assist A.T. Holdings II Sàrl, which beneficially owns 18,330,548 common shares, with registering at least 12,000,000 shares for a potential public offering.
- A.T. Holdings II agreed to a 365-day lockup beginning on the date of the final prospectus, subject to specified exceptions, including the potential offering, certain transfers and pledges to Oaktree.
- If the offering did not occur by February 16, 2023, the Auven Agreement would expire.
- Under a February 2, 2023 settlement term sheet, at least $49 million of net offering proceeds would be used to repay a portion of A.T. Holdings II’s obligations under its Oaktree-related credit facility.
- The parties contemplated an amended credit agreement with a maturity date of April 15, 2024, subject to conditions and execution.
- Oaktree and related lenders could receive share distributions equal to 25% of specified remaining A.T. Holdings II shares if obligations were not repaid within 14 days after the offering, or 15% if repayment occurred within that period.
- If the contemplated transactions failed or defaults occurred, the lenders could foreclose on common shares pledged by A.T. Holdings II. The filing states that the company itself is not the borrower under the described A.T. Holdings II facility, but its shares may be affected by foreclosure or related transactions.
Outlook, Risks and Unusual Items
- Management continued to expect double-digit product-revenue growth in 2023 compared with 2022.
- New regulations under the Infrastructure Investment and Jobs Act were expected to increase 2023 gross-to-net sales deductions by a mid-to-high single-digit percentage-point amount because of refunds related to discarded portions of certain single-dose drugs.
- The company believes ZYNLONTA could reach peak annual sales of $500 million to $1 billion, although this is a long-term potential estimate rather than a reported forecast for 2023.
- Key risks include commercialization and market acceptance of ZYNLONTA, reimbursement, partner execution and regulatory approvals, clinical-trial outcomes, regulatory timing, indebtedness and debt-service requirements, access to capital, and completion of the Auven, Oaktree and settlement transactions.
- The company believes it may have been a passive foreign investment company for 2022 and may be a PFIC in 2023 or later years, potentially creating adverse U.S. tax consequences for U.S. shareholders.
- The preliminary financial information was not audited, reviewed or otherwise assured by PricewaterhouseCoopers SA and may change when closing procedures are completed.
Important Facts for Investors to Verify
- Final fourth-quarter and full-year 2022 financial statements, including revenue, net loss, operating cash flow, margins, debt and cash runway.
- Whether the proposed A.T. Holdings II share offering closed, its final size and price, and the amount of proceeds applied to debt repayment.
- Whether the amended Oaktree credit agreement and related distribution agreements were executed, including the final maturity, covenants and share-distribution terms.
- Whether any foreclosure, transfer or substantial public-market sale of pledged shares occurred and its potential effect on share price and ownership.
- The realized impact of the Infrastructure Investment and Jobs Act refund rules on ZYNLONTA gross-to-net deductions and 2023 revenue growth.
- The company’s final PFIC determination and availability of information needed for potential qualified electing fund or mark-to-market elections.